Clinical Trials Logo

Treatment-Resistant clinical trials

View clinical trials related to Treatment-Resistant.

Filter by:
  • None
  • Page 1

NCT ID: NCT03116425 Active, not recruiting - Treatment Resistant Clinical Trials

Personalized Non-invasive Neuromodulation by rTMS for Chronic and Treatment Resistant Catatonia

RETONIC
Start date: April 24, 2017
Phase: N/A
Study type: Interventional

Investigators hypothesize that personalizing rTMS targets using functional MRI will allow to improve symptoms of patients suffering from chronic catatonia.

NCT ID: NCT02863380 Terminated - Depressive Disorder Clinical Trials

Personalized rTMS for Resistant Depression

Start date: May 4, 2016
Phase: N/A
Study type: Interventional

The investigators hypothesize that personalizing the rTMS targets using functional MRI will increase its efficacy. The most dysfunctional regions or the most dysfunctional network will be stimulated homogeneously. Individualized rTMS will be compared to traditional rTMS procedure and to trans-cranial direct current stimulation (tDCS) in a randomized cross-over trial. In this pilot study the primary outcome measure will be the correction of the MRI anomalies. Symptoms reduction and the proportion of remitters will be secondary outcome measurements.

NCT ID: NCT02410421 Withdrawn - Depressive Disorder Clinical Trials

e-PAT Neuromod Evaluation of Personalized rTMS for Resistant Depression

Start date: n/a
Phase: Phase 2
Study type: Interventional

Although repetitive trans-cranial magnetic stimulation (rTMS) is an effective therapy for resistant depression, it still fail to remit up to 70% of these patients. We hypothesize that personalizing the procedure using functional MRI to better select dysfunctional regions and robotic coil placement to stimulate these regions homogeneously, will increase its efficacy. Individualized rTMS will be compared to traditional rTMS procedure and to trans-cranial direct current stimulation (tDCS). In this small proof of principle study our primary outcome measure will be the correction of the MRI anomalies. Symptoms reduction and the proportion of remitters will be secondary outcome measurements.

NCT ID: NCT01882829 Completed - Clinical trials for Major Depressive Disorder

Nuedexta in Treatment-Resistant Major Depression

Start date: July 2013
Phase: Phase 2
Study type: Interventional

There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD. The current project aims to test the safety, tolerability and efficacy of Nuedexta - containing the NMDA antagonist dextromethorphan.